Nigeria is set to become one of the first countries to deploy a new malaria vaccine after receiving an initial batch of 846,200 doses. Developed by scientists at the University of Oxford and produced by the Serum Institute of India and Novavax, the R21 vaccine marks a significant step in the country’s fight against malaria.
Health Minister Muhammad Ali Pate noted that these doses are crucial for eliminating malaria, a disease that affects around 97% of the Nigerian population. Nigeria is the hardest-hit country globally, accounting for 31% of malaria-related deaths.
The vaccines, acquired in partnership with the international Vaccine Alliance, Gavi, will be provided free of charge. A trial rollout will start in Kebbi and Bayelsa, the states with the highest malaria burden, before expanding nationwide. An additional 153,800 doses are expected to arrive on October 26, bringing the total to nearly one million.